Seattle biotech Atossa Therapeutics eyes acquisition of unnamed company

Atossa has paid $3 million for exclusive rights to negotiate the deal. The target company focuses on a form of cancer treatment.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.